Pancreatic Cancer: A Review and Update

Dunphy, Elizabeth Prechtel

doi:10.1188/08.cjon.735-741

Cited by 22 publications

(15 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…7 and 8). This effect is correlated to the specificity of gemcitabine treatment for pancreatic cancer [45,46] and to the effectiveness of the drug against this aggressive form of cancer [47]. An increase in in vitro anticancer activity was observed for gemcitabine-loaded SVAs and FT-SVAs when compared to the free drug and conventional liposomes after 24 h of treatment.…”

Section: In Vitro Anticancer Activitymentioning

confidence: 74%

Folate-targeted supramolecular vesicular aggregates based on polyaspartyl-hydrazide copolymers for the selective delivery of antitumoral drugs

Licciardi¹,

Paolino²,

Celia³

et al. 2010

Biomaterials

View full text Add to dashboard Cite

Section: In Vitro Anticancer Activitymentioning

confidence: 74%

Folate-targeted supramolecular vesicular aggregates based on polyaspartyl-hydrazide copolymers for the selective delivery of antitumoral drugs

Licciardi¹,

Paolino²,

Celia³

et al. 2010

Biomaterials

View full text Add to dashboard Cite

“…Pancreatic cancer is among the most fatal of all major epithelial cancers with an incidence rate that approximates its mortality rate [1]. In 2009, the American Cancer Society estimated that 42,470 new patients were diagnosed with and 35,240 deaths resulted from pancreatic cancer in the U.S., making it the 4th leading cause of cancer mortality among both sexes [2].…”

Section: Introductionmentioning

confidence: 99%

Incidence rates of exocrine and endocrine pancreatic cancers in the United States

Zhou¹,

Enewold²,

Stojadinovic

et al. 2010

Cancer Causes Control

View full text Add to dashboard Cite

Descriptive studies of pancreatic cancer incidence have been sparse particularly in terms of tumor histology and stage. The purpose of this study was to examine the incidence rate trends of exocrine and endocrine pancreatic cancers by demographic and tumor characteristics using data from the Surveillance, Epidemiology, and End Results (SEER) program from 1977 to 2005. During this period, the incidence of exocrine pancreatic cancer generally decreased whereas the incidence of endocrine pancreatic cancer increased. This difference in trends by histology was evident across age, gender, and racial groups. It was also evident among different racial/ethnic groups using data from 1992 to 2005. Variation in trends was observed by stage. The incidence of exocrine cancers declined for all stages except regional. Endocrine cancer incidence increased for all tumor stages, and the increase was most prominent for localized tumors. When exocrine tumors were stratified by tumor subsite, the incidence of cancers in the tail and body regions increased while the incidence in other regions decreased. While better detection and classification of tumors through improved diagnostic procedures may be related to these changing trends, etiologic factors warrant study.

show abstract

“…The combination of M 2 ES and gemcitabine was generally well tolerated, with no pharmacokinetic interaction in patients with inoperable, locally advanced or metastatic pancreatic adenocarcinoma. Full therapeutic doses of M 2 ES (5-45 mg̸m 2 ) and gemcitabine (1,000 mg̸m 2 ) may be administered without reaching an MTD. A phase II clinical study is required to further evaluate the safety and efficacy of the combination of M 2 ES and gemcitabine for the treatment of patients with advanced pancreatic cancer.…”

Section: Discussionmentioning

confidence: 99%

“…Pancreatic cancer is amongst the deadliest types of cancer, with a 5-year survival rate of 3-5% (1,2). The diversity of the abnormalities in multiple aspects during malignant transformation, resulting in tumor heterogeneity in the majority of cancers, is one of the major challenges in cancer therapeutics.…”

Section: Introductionmentioning

confidence: 99%

Phase I trial of M2ES, a novel polyethylene glycosylated recombinant human endostatin, plus gemcitabine in advanced pancreatic cancer

Chen

et al. 2014

Molecular and Clinical Oncology

View full text Add to dashboard Cite

Abstract. Pancreatic cancer is one of the most lethal and resistant to treatment of solid tumors. Combination therapies with various types of drugs against pancreatic cancer have been extensively investigated. Endostatin is a potent endogenous inhibitor of angiogenesis, which may be administered in combination with various chemotherapeutic agents in the treatment of several types of cancer. To the best of our knowledge, this phase I trial was the first clinical study to determine the tolerance, safety and efficacy of M 2 ES, a novel polyethylene glycosylated recombinant human endostatin, administered concurrently with full-dose gemcitabine in patients with inoperable, locally advanced or metastatic pancreatic adenocarcinoma. A total of 16 patients were treated with gemcitabine (1,000 mg̸m 2 on days 1, 8 and 15) and M 2 ES (5-45 mg̸m 2 on days 1, 8, 15 and 21) of each 28-day cycle. In 15 evaluable patients, the stable disease rate (SDR) was 40% (95% CI: 11.9-68.1%). In particular, a 75% SDR was observed in 3 out of 4 patients with a M 2 ES dose level of 7.5 mg/m 2 . The most noticeable M 2 ES-related adverse events observed during the trial were grade 2 liver function abnormalities (6.3%) and grade 1 skin rash (6.3%). No dose-limiting toxicity was observed in any patients from all the dose levels. Therefore, there was no increased toxicity associated with the addition of M 2 ES to gemcitabine and this combination was well tolerated.

show abstract

Pancreatic Cancer: A Review and Update

Cited by 22 publications

References 18 publications

Folate-targeted supramolecular vesicular aggregates based on polyaspartyl-hydrazide copolymers for the selective delivery of antitumoral drugs

Folate-targeted supramolecular vesicular aggregates based on polyaspartyl-hydrazide copolymers for the selective delivery of antitumoral drugs

Incidence rates of exocrine and endocrine pancreatic cancers in the United States

Phase I trial of M2ES, a novel polyethylene glycosylated recombinant human endostatin, plus gemcitabine in advanced pancreatic cancer

Contact Info

Product

Resources

About